C. R. Bard, Inc. (U.S.) held the second position in the global vascular access devices market in 2016.

The company offers vascular access devices through its Oncology segment. The Oncology segment offers a wide range of implantable ports used in chemotherapy. The company has a strong foot hold in the United States, European and Asia-Pacific market. The company is to be acquired by Becton Dickinson and Company (U.S.) in 2017.

Download FREE Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=122149686

Smiths Medical, Inc. (U.K.) is another leading player in the market.

The company focuses on organic growth strategies like product development. The company focuses on R&D as a part of its growth strategy. The revenue of the company was USD 1.2 billion in 2016 out which approximately 2-5% was spent on R&D.

“Vascular Access Device Market by Type (Peripheral (Midline, Short), Central (PICC, Tunneled, Non-Tunneled, Implanted Ports), Accessories), Application (Drug Administration, Fluid & Nutrition Administration) & End Users – Global Forecasts to 2022”

The global vascular access devices market is projected to reach USD 5.45 Million by 2022 from USD 3.87 Million in 2017, at a CAGR of 7.1% during the forecast period.

This is an emerging and fragmented market with various regional and national players. In 2016, Becton Dickinson and Company (U.S.) dominated the peripheral vascular access devices market and accounted for approximately 67% of the market share. Whereas, the central venous access devices market was dominated by C. R. Bard, Inc. (U.S.), and Smiths Medical, Inc. (U.K) which, together, held ~70% of the market.

To Know More @ https://www.marketsandmarkets.com/Market-Reports/vascular-access-device-market-122149686.html